A5057315407- Bladder and Urothelial Cancer Treatments
- Gut microbiota and health
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
Queen's University
2022-2024
Queens University
2022
Abstract Poor response to Bacillus Calmette-Guérin (BCG) immunotherapy remains a major barrier in the management of patients with non–muscle invasive bladder cancer (NMIBC). Multiple factors are associated poor outcomes, including biological aging and female sex. More recently, it has emerged that B-cell–infiltrated pretreatment immune microenvironment NMIBC tumors can influence intravesically administered BCG. The mechanisms underlying roles B cells poorly understood. Here, we show...
<div>Abstract<p>Poor response to Bacillus Calmette-Guérin (BCG) immunotherapy remains a major barrier in the management of patients with non–muscle invasive bladder cancer (NMIBC). Multiple factors are associated poor outcomes, including biological aging and female sex. More recently, it has emerged that B‐cell–infiltrated pretreatment immune microenvironment NMIBC tumors can influence intravesically administered BCG. The mechanisms underlying roles B cells poorly understood....
Abstract Poor response to Bacillus Calmette-Guérin (BCG) immunotherapy remains a major barrier in the management of patients with non-muscle-invasive bladder cancer (NMIBC). Among multiple factors contributing poor outcomes, B cell infiltrated pre-treatment immune microenvironment NMIBC tumors has emerged as key determinant BCG. The mechanisms underlying paradoxical roles cells are poorly understood. Here, we show that dominant tertiary lymphoid structures (TLSs), hallmark feature chronic...
<p>Gating strategy for identifying different subsets of T cells.</p>
<p>B‐cell depletion alters expression profiles of immune regulatory genes in the bladder microenvironment.</p>
<p>Contour plots showing myeloid and T cell populations.</p>
<p>Tumor-adjacent TLS characterized using multiplex IF and NanoString GeoMx DSP.</p>
<p>Effect of transient B‐cell depletion and BBN exposure on urothelium exposed female male mice.</p>
<p>BBN exposure and BCG treatment alters plasma immunoglobulin profiles in a sex differential manner.</p>
<p>Gating strategy for identifying atypical B cells (ABCs) and myeloid cell population.</p>
<p>Immune infiltration in the bladder microenvironment after repeated BCG treatment and B‐cell depletion BBN exposed mice.</p>
<p>Splenic ABC expansion is enhanced by a combination of BBN exposure and BCG treatment.</p>
<p>Expansion of ABCs in the systemic and local bladder microenvironment.</p>
<p>B‐cell differentiation to ABCs following in vitro treatment with IFN-<i>γ</i>, IL-21 and BCG is sex-dependent.</p>
Abstract Non-muscle invasive bladder cancer (NMIBC) constitutes a significant clinical challenge, with over 50% of patients experiencing poor outcomes in the form early recurrence or progression following treatment Bacillus Calmette-Guerin (BCG) immunotherapy. The pre-treatment tumor immune microenvironment (TIME) is an established determinant response to BCG. This study explores spatial profiles CD79a+ B cells, CD163+ M2-like macrophages, proliferating and tissue-resident phenotypes T along...